Biologic Response Modifiers Market
Number of pages: 100 | Report Format: PDF | Published date: June 02, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
11% |
|
Base Year of Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Application, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global biologic response modifiers market is expected to grow at a revenue CAGR of 11% from 2023 to 2031.
Biologic Response Modifiers Market Fundamentals
Biologic response modifiers (BRMs), also known as biologic agents or biologics, are medications designed to modify the body's immune response. Biologic response modifiers are typically derived from living sources, such as human or animal cells, and they are produced using biotechnology techniques. They work by targeting specific immune system components to suppress or enhance their activity, depending on the condition being treated. Unlike traditional small molecule drugs, which are typically synthesized chemically, biologic response modifiers are larger, more complex molecules, often proteins or antibodies. They are usually administered via injection or infusion and have a targeted mechanism of action, such as blocking specific pro-inflammatory molecules or modulating the activity of certain immune cells. By modulating the immune response, biologic response modifiers help to reduce inflammation and prevent damage to tissues and organs caused by an overactive immune system. They have revolutionized the treatment of many autoimmune diseases and have shown significant efficacy in improving symptoms, slowing disease progression, and improving patients' overall quality of life.
Biologic Response Modifiers Market Dynamics
Autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, are rising globally. The growing prevalence of these conditions creates a higher demand for effective treatment options, including biologic response modifiers. According to the European Federation of Crohn's and Ulcerative Colitis Associations, around 10 million people worldwide live with inflammatory bowel disease. Biologic response modifiers initially gained traction in treating autoimmune diseases like rheumatoid arthritis and psoriasis. However, there is a growing biologic response modifiers industry trend of exploring their potential in other therapeutic areas, such as oncology, ophthalmology, and neurology. According to GLOBOCAN 2020 report, approximately 10 million deaths were cases of cancer in 2020. Research is underway to investigate the efficacy of biologic response modifiers in cancer immunotherapy, macular degeneration, multiple sclerosis, and other conditions, opening up new opportunities for market growth. According to the National Centre for Biotechnology Information, the number of persons with multiple sclerosis globally in 2020 was estimated to be around 2.8 million, or 35.9 per 100,000 people, which is 30% more than in 2013. Biologic response modifiers have demonstrated high efficacy in managing autoimmune diseases and cancer, often achieving better outcomes than traditional therapies. They are designed to specifically target and modulate immune system components involved in disease pathogenesis, resulting in improved symptom control and management. The field of biotechnology has witnessed significant advancements, enabling the development of complex biologic molecules with improved efficacy and safety profiles. Innovations in protein engineering, monoclonal antibody technology, and genetic engineering techniques have facilitated the production of more potent and targeted biologic response modifiers, which is also expected to boost the biologic response modifiers market growth.
However, biologic response modifiers are often expensive compared to traditional therapies. The complex manufacturing processes involved in producing biologic drugs and research and development costs contribute to their high price tags, which restrict the biologic response modifiers market growth. Biologic response modifiers are subject to rigorous regulatory scrutiny due to their complex nature and potential risks. Obtaining regulatory approvals can be a time-consuming and costly process, which is also cramping the growth of the biologic response modifiers market.
Biologic Response Modifiers Market Ecosystem
The global biologic response modifiers market is analyzed from three perspectives: type, application, and region.
Biologic Response Modifiers Market by Type
Based on the types, the global biologic response modifiers market is segmented into monoclonal antibodies, interleukins, interferons, TNF-α, tyrosine kinase inhibitors, colony stimulating factors, tumor vaccines, angiogenic inhibitors, and others.
The monoclonal antibodies segment accounted for the largest revenue share of the biologic response modifiers market in 2022. Monoclonal antibodies have a proven track record of efficacy and safety in treating various diseases. They have been extensively studied and approved for use in autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. The established therapeutic benefits and well-documented clinical outcomes have led to their widespread adoption and acceptance among healthcare professionals and patients. According to the National Centre for Biotechnology Information, around 2-3% of the world's population suffers from psoriasis; in some Northern European nations, that number rises to 8-11%. Adult prevalence of psoriasis ranges from 0.91 to 8.5%, whereas that of children ranges from 0.0 to 2.1%.
Monoclonal antibodies are designed to bind to specific targets, such as cytokines, cell surface receptors, or immune cells. This targeted action allows for precise modulation of the immune response and inhibition of disease processes. Monoclonal antibodies have a broad range of therapeutic applications beyond autoimmune diseases. They are increasingly used in oncology for targeted cancer therapy, with numerous mAbs approved for various types of cancer. Monoclonal antibodies are also being explored in treating infectious diseases, cardiovascular disorders, neurological conditions, and more. Monoclonal antibodies have been the focus of extensive research and development efforts. This has led to the discovery and development of novel mAbs, improved manufacturing processes, and enhanced understanding of their mechanisms of action, which is also boosting segmental growth.
Biologic Response Modifiers Market by Application
Based on the applications, the global biologic response modifiers market is segmented into autoimmune diseases, cancer, and others.
The autoimmune diseases segment accounted for a significant biologic response modifiers market share in 2022. The prevalence and incidence of autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, are increasing. As these diseases often require long-term management, a substantial and sustained demand for effective treatments exists. The prevalence and incidence of autoimmune diseases are increasing globally. As these diseases often require long-term management, a substantial and sustained demand for effective treatments exists. According to the National Stem Cell Foundation, around 4% of the world’s population is affected by one of more than 80 different autoimmune diseases. Biologic response modifiers, especially monoclonal antibodies, have achieved numerous approvals for treating autoimmune diseases. These approvals are based on extensive clinical trials demonstrating their efficacy and safety in managing symptoms, reducing inflammation, and slowing disease progression. The availability of approved biologic response modifiers and their established track record contributes to their growth in the autoimmune diseases segment. Autoimmune diseases are characterized by an overactive immune response targeting the body's own tissues. Biologic response modifiers offer a tailored treatment approach by specifically targeting key immune system components involved in the disease process. This targeted approach allows for better disease control while minimizing non-specific immune suppression, resulting in improved treatment outcomes and reduced side effects.
Biologic Response Modifiers Market by Region
Geographically, the global biologic response modifiers market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The North America region has the largest biologic response modifiers market size in terms of revenue generation accounting for around 37.8% share of the market. The rising incidence and prevalence of these autoimmune diseases drive the demand for effective treatments, including biologic response modifiers. The growing patient population with autoimmune diseases fuels the market growth in North America. The American Autoimmune Related Diseases Association (AARDA) estimates that up to 50 million people in the U.S. suffer from an autoimmune disease, at a cost of $86 billion each year. North America has a robust healthcare infrastructure, including advanced healthcare facilities, research institutions, and specialized clinics. The availability of well-equipped healthcare settings supports biologic response modifiers' development, manufacturing, and distribution. The strong healthcare infrastructure also facilitates the adoption and utilization of biologic response modifiers by healthcare professionals and patients. North America is a hub for technological advancements and innovation in the healthcare sector. The region witnesses significant research and development activities related to biologic response modifiers, including developing novel monoclonal antibodies, cytokine inhibitors, and other targeted therapies. There is a growing focus on personalized medicine in North America, which aligns with the targeted approach of biologic response modifiers. Biologic response modifiers, with their ability to target specific components of the immune system, offer personalized treatment options that address the specific needs of patients. The emphasis on personalized medicine drives the demand for biologic response modifiers in North America.
Biologic Response Modifiers Market Competitive Landscape
The prominent players operating in the global biologic response modifiersmarket are:
Biologic Response Modifiers Market Strategic Developments
Biologic response modifiers (BRMs), also known as biologic agents or biologics, are a class of medications that are designed to modify the body's immune response. Biologic response modifiers are typically derived from living sources, such as human or animal cells, and they are produced using biotechnology techniques.
Market players focus on developing new and innovative BRMs to address unmet medical needs and expand their product portfolios. They invest in research and development activities to enhance the efficacy, safety, and convenience of existing BRMs or develop novel therapies with improved therapeutic profiles.
The prominent players operating in the global biologic response modifiers market are Bristol-Myers Squibb Company, Novartis AG, Swedish Orphan Biovitrum AB, AbbVie Inc., and Amgen Inc.
The global biologic response modifiers market growth is estimated to grow at a revenue CAGR of 11% during the forecast period from 2023 to 2031.
Asia Pacific can be considered the key growth region due to the surge in biologic response modifiers industry trends in China, Japan, and the Indian subcontinent.
*Insights on financial performance are subject to the availability of information in the public domain